ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Generic Injectables Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Published Date: June 2025
|
Report Code: QYRE-Auto-32B9066
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Generic Injectables Market Insights and Forecast to 2028
BUY CHAPTERS

Global Generic Injectables Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-32B9066
Report
June 2025
Pages:138
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz(Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd.
Grifols S A
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
AuroMedics
Sanofi
Gland Pharma
Endo International Plc.

Generic Injectables Market Size

In 2024, the global market size of Generic Injectables was estimated to be worth US$ 32770 million and is forecast to reach approximately US$ 41560 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.

Generic Injectables Market

Generic Injectables Market

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Generic Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Injectables.
The Generic Injectables market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Generic Injectables market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation

Scope of Generic Injectables Market Report

Report Metric Details
Report Name Generic Injectables Market
CAGR 3.5%
Segment by Type
  • Small Molecule
  • Large Molecule
Segment by Application
  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular Diseases
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma, Endo International PLC
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
  • Chapter 2: Revenue of Generic Injectables in global and regional level.
  • Chapter 3: Detailed analysis of Generic Injectables company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Injectables revenue, gross margin, and recent development, etc.
  • Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: Research Findings and Conclusion

FAQ for this report

What is the market share of major companies in Generic Injectables Market?

Ans: Top two players hold a share about 27% in 2019.

Who are the main players in the Generic Injectables Market report?

Ans: The main players in the Generic Injectables Market are Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma, Endo International PLC

What are the Application segmentation covered in the Generic Injectables Market report?

Ans: The Applications covered in the Generic Injectables Market report are Oncology, Anesthesia, Anti-Infectives, Parenteral Nutrition, Cardiovascular Diseases

What are the Type segmentation covered in the Generic Injectables Market report?

Ans: The Types covered in the Generic Injectables Market report are Small Molecule, Large Molecule

1 Study Coverage
1.1 Generic Injectables Product Introduction
1.2 Market by Type
1.2.1 Global Generic Injectables Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Small Molecule
1.2.3 Large Molecule
1.3 Market by Application
1.3.1 Global Generic Injectables Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Oncology
1.3.3 Anesthesia
1.3.4 Anti-Infectives
1.3.5 Parenteral Nutrition
1.3.6 Cardiovascular Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Generic Injectables Market Size Estimates and Forecasts
2.2 Generic Injectables Market Size by Region: 2024 Versus 2031
2.2.1 Global Generic Injectables Revenue by Region: 2020-2025
2.2.2 Global Generic Injectables Revenue Forecast by Region (2026-2031)
2.2.3 Global Generic Injectables Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Generic Injectables Revenue by Type (2020-2031)
3.1.2 Global Generic Injectables Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Generic Injectables Revenue by Application (2020-2031)
3.2.2 Global Generic Injectables Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Small Molecule of Generic Injectables Revenue Market Share by Application
3.3.2 Large Molecule of Generic Injectables Revenue Market Share by Application
4 Global Generic Injectables by Company
4.1 Global Generic Injectables Revenue by Company (2020-2025)
4.2 Global Generic Injectables Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Generic Injectables Companies around the World: Ranking by Revenue
4.3.2 Global Generic Injectables Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Generic Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Generic Injectables Companies Headquarters & Product Type
4.4.1 Global Generic Injectables Companies Headquarters
4.4.2 Date of International Companies Enter into Generic Injectables Market
4.4.3 Global Generic Injectables Companies Product & Service
4.4.4 Small Molecule Revenue Market Share of Generic Injectables by Company
4.4.5 Large Molecule Revenue Market Share of Generic Injectables by Company
4.5 Global Generic Injectables Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Hospira (Pfizer Inc.)
5.1.1 Hospira (Pfizer Inc.) Corporation Information
5.1.2 Hospira (Pfizer Inc.) Description, Business Overview
5.1.3 Hospira (Pfizer Inc.) Generic Injectables Products Offered
5.1.4 Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (2020-2025)
5.1.5 Hospira (Pfizer Inc.) Generic Injectables Revenue by Product in 2024
5.1.6 Hospira (Pfizer Inc.) Generic Injectables Revenue by Application in 2024
5.1.7 Hospira (Pfizer Inc.) Generic Injectables Revenue by Geographic Area in 2024
5.1.8 Hospira (Pfizer Inc.) Recent Developments
5.2 Fresenius Kabi
5.2.1 Fresenius Kabi Corporation Information
5.2.2 Fresenius Kabi Description, Business Overview
5.2.3 Fresenius Kabi Generic Injectables Products Offered
5.2.4 Fresenius Kabi Generic Injectables Revenue and Gross Margin (2020-2025)
5.2.5 Fresenius Kabi Generic Injectables Revenue by Product in 2024
5.2.6 Fresenius Kabi Generic Injectables Revenue by Application in 2024
5.2.7 Fresenius Kabi Generic Injectables Revenue by Geographic Area in 2024
5.2.8 Fresenius Kabi Recent Developments
5.3 Sandoz (Novartis)
5.3.1 Sandoz (Novartis) Corporation Information
5.3.2 Sandoz (Novartis) Description, Business Overview
5.3.3 Sandoz (Novartis) Generic Injectables Products Offered
5.3.4 Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (2020-2025)
5.3.5 Sandoz (Novartis) Generic Injectables Revenue by Product in 2024
5.3.6 Sandoz (Novartis) Generic Injectables Revenue by Application in 2024
5.3.7 Sandoz (Novartis) Generic Injectables Revenue by Geographic Area in 2024
5.3.8 Sandoz (Novartis) Recent Developments
5.4 Hikma Pharmaceuticals PLC
5.4.1 Hikma Pharmaceuticals PLC Corporation Information
5.4.2 Hikma Pharmaceuticals PLC Description, Business Overview
5.4.3 Hikma Pharmaceuticals PLC Generic Injectables Products Offered
5.4.4 Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (2020-2025)
5.4.5 Hikma Pharmaceuticals PLC Generic Injectables Revenue by Product in 2024
5.4.6 Hikma Pharmaceuticals PLC Generic Injectables Revenue by Application in 2024
5.4.7 Hikma Pharmaceuticals PLC Generic Injectables Revenue by Geographic Area in 2024
5.4.8 Hikma Pharmaceuticals PLC Recent Developments
5.5 Dr. Reddy’s Laboratories Ltd
5.5.1 Dr. Reddy’s Laboratories Ltd Corporation Information
5.5.2 Dr. Reddy’s Laboratories Ltd Description, Business Overview
5.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Products Offered
5.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (2020-2025)
5.5.5 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue by Product in 2024
5.5.6 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue by Application in 2024
5.5.7 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue by Geographic Area in 2024
5.5.8 Dr. Reddy’s Laboratories Ltd Recent Developments
5.6 Grifols
5.6.1 Grifols Corporation Information
5.6.2 Grifols Description, Business Overview
5.6.3 Grifols Generic Injectables Products Offered
5.6.4 Grifols Generic Injectables Revenue and Gross Margin (2020-2025)
5.6.5 Grifols Generic Injectables Revenue by Product in 2024
5.6.6 Grifols Generic Injectables Revenue by Application in 2024
5.6.7 Grifols Generic Injectables Revenue by Geographic Area in 2024
5.6.8 Grifols Recent Developments
5.7 Nichi-Iko Group (Sagent)
5.7.1 Nichi-Iko Group (Sagent) Corporation Information
5.7.2 Nichi-Iko Group (Sagent) Description, Business Overview
5.7.3 Nichi-Iko Group (Sagent) Generic Injectables Products Offered
5.7.4 Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (2020-2025)
5.7.5 Nichi-Iko Group (Sagent) Generic Injectables Revenue by Product in 2024
5.7.6 Nichi-Iko Group (Sagent) Generic Injectables Revenue by Application in 2024
5.7.7 Nichi-Iko Group (Sagent) Generic Injectables Revenue by Geographic Area in 2024
5.7.8 Nichi-Iko Group (Sagent) Recent Developments
5.8 Teva Pharmaceutical
5.8.1 Teva Pharmaceutical Corporation Information
5.8.2 Teva Pharmaceutical Description, Business Overview
5.8.3 Teva Pharmaceutical Generic Injectables Products Offered
5.8.4 Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (2020-2025)
5.8.5 Teva Pharmaceutical Generic Injectables Revenue by Product in 2024
5.8.6 Teva Pharmaceutical Generic Injectables Revenue by Application in 2024
5.8.7 Teva Pharmaceutical Generic Injectables Revenue by Geographic Area in 2024
5.8.8 Teva Pharmaceutical Recent Developments
5.9 Auromedics
5.9.1 Auromedics Corporation Information
5.9.2 Auromedics Description, Business Overview
5.9.3 Auromedics Generic Injectables Products Offered
5.9.4 Auromedics Generic Injectables Revenue and Gross Margin (2020-2025)
5.9.5 Auromedics Generic Injectables Revenue by Product in 2024
5.9.6 Auromedics Generic Injectables Revenue by Application in 2024
5.9.7 Auromedics Generic Injectables Revenue by Geographic Area in 2024
5.9.8 Auromedics Recent Developments
5.10 Sanofi
5.10.1 Sanofi Corporation Information
5.10.2 Sanofi Description, Business Overview
5.10.3 Sanofi Generic Injectables Products Offered
5.10.4 Sanofi Generic Injectables Revenue and Gross Margin (2020-2025)
5.10.5 Sanofi Generic Injectables Revenue by Product in 2024
5.10.6 Sanofi Generic Injectables Revenue by Application in 2024
5.10.7 Sanofi Generic Injectables Revenue by Geographic Area in 2024
5.10.8 Sanofi Recent Developments
5.11 Gland Pharma
5.11.1 Gland Pharma Corporation Information
5.11.2 Gland Pharma Description, Business Overview
5.11.3 Gland Pharma Generic Injectables Products Offered
5.11.4 Gland Pharma Generic Injectables Revenue and Gross Margin (2020-2025)
5.11.5 Gland Pharma Generic Injectables Revenue by Product in 2024
5.11.6 Gland Pharma Generic Injectables Revenue by Application in 2024
5.11.7 Gland Pharma Generic Injectables Revenue by Geographic Area in 2024
5.11.8 Gland Pharma Recent Developments
5.12 Endo International PLC
5.12.1 Endo International PLC Corporation Information
5.12.2 Endo International PLC Description, Business Overview
5.12.3 Endo International PLC Generic Injectables Products Offered
5.12.4 Endo International PLC Generic Injectables Revenue and Gross Margin (2020-2025)
5.12.5 Endo International PLC Generic Injectables Revenue by Product in 2024
5.12.6 Endo International PLC Generic Injectables Revenue by Application in 2024
5.12.7 Endo International PLC Generic Injectables Revenue by Geographic Area in 2024
5.12.8 Endo International PLC Recent Developments
6 North America
6.1 North America Generic Injectables Market Size YoY Growth 2020-2031
6.2 North America Generic Injectables Market Facts & Figures by Country (2020-2031)
6.3 North America Generic Injectables Revenue by Type (2020-2025)
6.4 North America Generic Injectables Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Generic Injectables Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Generic Injectables Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Generic Injectables Revenue by Type (2020-2025)
7.4 Asia-Pacific Generic Injectables Revenue by Application (2020-2025)
8 Europe
8.1 Europe Generic Injectables Market Size YoY Growth 2020-2031
8.2 Europe Generic Injectables Market Facts & Figures by Country (2020-2031)
8.3 Europe Generic Injectables Revenue by Type (2020-2025)
8.4 Europe Generic Injectables Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Generic Injectables Market Size YoY Growth 2020-2031
9.2 Latin America Generic Injectables Market Facts & Figures by Country (2020-2031)
9.3 Latin America Generic Injectables Revenue by Type (2020-2025)
9.4 Latin America Generic Injectables Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Generic Injectables Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Generic Injectables Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Generic Injectables Revenue by Type (2020-2025)
10.4 Middle East and Africa Generic Injectables Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Generic Injectables Supply Chain Analysis
11.2 Generic Injectables Key Raw Materials and Upstream Suppliers
11.3 Generic Injectables Clients Analysis
11.4 Generic Injectables Sales Channel and Sales Model Analysis
11.4.1 Generic Injectables Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Generic Injectables Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Generic Injectables Distributors
12 Generic Injectables Market Dynamics
12.1 Generic Injectables Industry Trends
12.2 Generic Injectables Market Drivers
12.3 Generic Injectables Market Challenges
12.4 Generic Injectables Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
FEATURED COMPANIES
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz(Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd.
Grifols S A
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
AuroMedics
Sanofi
Gland Pharma
Endo International Plc.
List of Tables
 Table 1. Global Generic Injectables Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Generic Injectables Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Generic Injectables Market Size by Region (US$ Million): 2024 VS 2031
 Table 4. Global Generic Injectables Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Generic Injectables Revenue Forecast by Region (2026-2031) & (US$ Million)
 Table 6. Global Generic Injectables Revenue by Type (2020-2025) & (US$ Million)
 Table 7. Global Generic Injectables Revenue Forecast by Type (2026-2031) & (US$ Million)
 Table 8. Global Generic Injectables Revenue by Application (2020-2025) & (US$ Million)
 Table 9. Global Generic Injectables Revenue Forecast by Application (2026-2031) & (US$ Million)
 Table 10. Generic Injectables Revenue by Company (2020-2025) & (US$ Million)
 Table 11. Generic Injectables Revenue Share by Company (2020-2025)
 Table 12. Ranking of Global Top Generic Injectables Players by Revenue (US$ Million) in 2024
 Table 13. Global Generic Injectables Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
 Table 14. Global Generic Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Injectables as of 2024)
 Table 15. Global Generic Injectables Companies Headquarters
 Table 16. Date of International Companies Enter into Generic Injectables Market
 Table 17. Global Generic Injectables Companies Product & Service
 Table 18. Global Generic Injectables Mergers & Acquisitions, Expansion Plans
 Table 19. Hospira (Pfizer Inc.) Corporation Information
 Table 20. Hospira (Pfizer Inc.) Description and Business Overview
 Table 21. Hospira (Pfizer Inc.) Generic Injectables Product
 Table 22. Hospira (Pfizer Inc.) Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 23. Hospira (Pfizer Inc.) Revenue Proportion of Generic Injectables by Product in 2024
 Table 24. Hospira (Pfizer Inc.) Revenue Proportion of Generic Injectables by Application in 2024
 Table 25. Hospira (Pfizer Inc.) Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 26. Hospira (Pfizer Inc.) Recent Developments
 Table 27. Fresenius Kabi Corporation Information
 Table 28. Fresenius Kabi Description and Business Overview
 Table 29. Fresenius Kabi Generic Injectables Product
 Table 30. Fresenius Kabi Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 31. Fresenius Kabi Revenue Proportion of Generic Injectables by Product in 2024
 Table 32. Fresenius Kabi Revenue Proportion of Generic Injectables by Application in 2024
 Table 33. Fresenius Kabi Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 34. Fresenius Kabi Recent Developments
 Table 35. Sandoz (Novartis) Corporation Information
 Table 36. Sandoz (Novartis) Description and Business Overview
 Table 37. Sandoz (Novartis) Generic Injectables Product
 Table 38. Sandoz (Novartis) Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 39. Sandoz (Novartis) Revenue Proportion of Generic Injectables by Product in 2024
 Table 40. Sandoz (Novartis) Revenue Proportion of Generic Injectables by Application in 2024
 Table 41. Sandoz (Novartis) Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 42. Sandoz (Novartis) Recent Developments
 Table 43. Hikma Pharmaceuticals PLC Corporation Information
 Table 44. Hikma Pharmaceuticals PLC Description and Business Overview
 Table 45. Hikma Pharmaceuticals PLC Generic Injectables Product
 Table 46. Hikma Pharmaceuticals PLC Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Hikma Pharmaceuticals PLC Revenue Proportion of Generic Injectables by Product in 2024
 Table 48. Hikma Pharmaceuticals PLC Revenue Proportion of Generic Injectables by Application in 2024
 Table 49. Hikma Pharmaceuticals PLC Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 50. Hikma Pharmaceuticals PLC Recent Developments
 Table 51. Dr. Reddy’s Laboratories Ltd Corporation Information
 Table 52. Dr. Reddy’s Laboratories Ltd Description and Business Overview
 Table 53. Dr. Reddy’s Laboratories Ltd Generic Injectables Product
 Table 54. Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 55. Dr. Reddy’s Laboratories Ltd Revenue Proportion of Generic Injectables by Product in 2024
 Table 56. Dr. Reddy’s Laboratories Ltd Revenue Proportion of Generic Injectables by Application in 2024
 Table 57. Dr. Reddy’s Laboratories Ltd Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 58. Dr. Reddy’s Laboratories Ltd Recent Developments
 Table 59. Grifols Corporation Information
 Table 60. Grifols Description and Business Overview
 Table 61. Grifols Generic Injectables Product
 Table 62. Grifols Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 63. Grifols Revenue Proportion of Generic Injectables by Product in 2024
 Table 64. Grifols Revenue Proportion of Generic Injectables by Application in 2024
 Table 65. Grifols Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 66. Grifols Recent Developments
 Table 67. Nichi-Iko Group (Sagent) Corporation Information
 Table 68. Nichi-Iko Group (Sagent) Description and Business Overview
 Table 69. Nichi-Iko Group (Sagent) Generic Injectables Product
 Table 70. Nichi-Iko Group (Sagent) Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 71. Nichi-Iko Group (Sagent) Revenue Proportion of Generic Injectables by Product in 2024
 Table 72. Nichi-Iko Group (Sagent) Revenue Proportion of Generic Injectables by Application in 2024
 Table 73. Nichi-Iko Group (Sagent) Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 74. Nichi-Iko Group (Sagent) Recent Developments
 Table 75. Teva Pharmaceutical Corporation Information
 Table 76. Teva Pharmaceutical Description and Business Overview
 Table 77. Teva Pharmaceutical Generic Injectables Product
 Table 78. Teva Pharmaceutical Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 79. Teva Pharmaceutical Revenue Proportion of Generic Injectables by Product in 2024
 Table 80. Teva Pharmaceutical Revenue Proportion of Generic Injectables by Application in 2024
 Table 81. Teva Pharmaceutical Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 82. Teva Pharmaceutical Recent Developments
 Table 83. Auromedics Corporation Information
 Table 84. Auromedics Description and Business Overview
 Table 85. Auromedics Generic Injectables Product
 Table 86. Auromedics Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 87. Auromedics Revenue Proportion of Generic Injectables by Product in 2024
 Table 88. Auromedics Revenue Proportion of Generic Injectables by Application in 2024
 Table 89. Auromedics Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 90. Auromedics Recent Developments
 Table 91. Sanofi Corporation Information
 Table 92. Sanofi Description and Business Overview
 Table 93. Sanofi Generic Injectables Product
 Table 94. Sanofi Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 95. Sanofi Revenue Proportion of Generic Injectables by Product in 2024
 Table 96. Sanofi Revenue Proportion of Generic Injectables by Application in 2024
 Table 97. Sanofi Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 98. Sanofi Recent Developments
 Table 99. Gland Pharma Corporation Information
 Table 100. Gland Pharma Description and Business Overview
 Table 101. Gland Pharma Generic Injectables Product
 Table 102. Gland Pharma Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Gland Pharma Revenue Proportion of Generic Injectables by Product in 2024
 Table 104. Gland Pharma Revenue Proportion of Generic Injectables by Application in 2024
 Table 105. Gland Pharma Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 106. Gland Pharma Recent Developments
 Table 107. Endo International PLC Corporation Information
 Table 108. Endo International PLC Description and Business Overview
 Table 109. Endo International PLC Generic Injectables Product
 Table 110. Endo International PLC Generic Injectables Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 111. Endo International PLC Revenue Proportion of Generic Injectables by Product in 2024
 Table 112. Endo International PLC Revenue Proportion of Generic Injectables by Application in 2024
 Table 113. Endo International PLC Revenue Proportion of Generic Injectables by Geographic Area in 2024
 Table 114. Endo International PLC Recent Developments
 Table 115. North America Generic Injectables Revenue by Country (2020-2025) & (US$ Million)
 Table 116. North America Generic Injectables Revenue by Country (2026-2031) & (US$ Million)
 Table 117. North America Generic Injectables Revenue by Type (2020-2025) & (US$ Million)
 Table 118. North America Generic Injectables Revenue by Application (2020-2025) & (US$ Million)
 Table 119. Asia-Pacific Generic Injectables Revenue by Region (2020-2025) & (US$ Million)
 Table 120. Asia-Pacific Generic Injectables Revenue by Region (2026-2031) & (US$ Million)
 Table 121. Asia-Pacific Generic Injectables Revenue by Type (2020-2025) & (US$ Million)
 Table 122. Asia-Pacific Generic Injectables Revenue by Application (2020-2025) & (US$ Million)
 Table 123. Europe Generic Injectables Revenue by Country (2020-2025) & (US$ Million)
 Table 124. Europe Generic Injectables Revenue by Country (2026-2031) & (US$ Million)
 Table 125. Europe Generic Injectables Revenue by Type (2020-2025) & (US$ Million)
 Table 126. Europe Generic Injectables Revenue by Application (2020-2025) & (US$ Million)
 Table 127. Latin America Generic Injectables Revenue by Country (2020-2025) & (US$ Million)
 Table 128. Latin America Generic Injectables Revenue by Country (2026-2031) & (US$ Million)
 Table 129. Latin America Generic Injectables Revenue by Type (2020-2025) & (US$ Million)
 Table 130. Latin America Generic Injectables Revenue by Application (2020-2025) & (US$ Million)
 Table 131. Middle East and Africa Generic Injectables Revenue by Country (2020-2025) & (US$ Million)
 Table 132. Middle East and Africa Generic Injectables Revenue by Country (2026-2031) & (US$ Million)
 Table 133. Middle East and Africa Generic Injectables Revenue by Type (2020-2025) & (US$ Million)
 Table 134. Middle East and Africa Generic Injectables Revenue by Application (2020-2025) & (US$ Million)
 Table 135. Generic Injectables Key Raw Materials, Industry Status and Trend
 Table 136. Generic Injectables Key Raw Materials and Upstream Suppliers
 Table 137. Generic Injectables Clients Status and Trend
 Table 138. Generic Injectables Typical Clients
 Table 139. Generic Injectables Distributors
 Table 140. Generic Injectables Market Trends
 Table 141. Generic Injectables Market Drivers
 Table 142. Generic Injectables Market Challenges
 Table 143. Generic Injectables Market Restraints
 Table 144. Research Programs/Design for This Report
 Table 145. Key Data Information from Secondary Sources
 Table 146. Key Data Information from Primary Sources


List of Figures
 Figure 1. Generic Injectables Product Picture
 Figure 2. Global Generic Injectables Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
 Figure 3. Global Generic Injectables Revenue Market Share by Type in 2024 & 2031
 Figure 4. Small Molecule Product Picture
 Figure 5. Large Molecule Product Picture
 Figure 6. Global Generic Injectables Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
 Figure 7. Global Generic Injectables Revenue Market Share by Application in 2024 & 2031
 Figure 8. Oncology
 Figure 9. Anesthesia
 Figure 10. Anti-Infectives
 Figure 11. Parenteral Nutrition
 Figure 12. Cardiovascular Diseases
 Figure 13. Generic Injectables Report Years Considered
 Figure 14. Global Generic Injectables Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Generic Injectables Market Size (2020-2031) & (US$ Million)
 Figure 16. Global Generic Injectables Market Size Market Share by Region: 2024 Versus 2031
 Figure 17. Global Generic Injectables Revenue Market Share by Region (2020-2031)
 Figure 18. Global Generic Injectables Revenue Market Share Forecast by Type (2020-2031)
 Figure 19. Global Generic Injectables Revenue Market Share Forecast by Application (2020-2031)
 Figure 20. Small Molecule of Generic Injectables Revenue Market Share by Application, 2024 VS 2031
 Figure 21. Large Molecule of Generic Injectables Revenue Market Share by Application, 2024 VS 2031
 Figure 22. Generic Injectables Revenue Share by Company (2024)
 Figure 23. Generic Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Small Molecule Revenue Proportion by Company in 2024
 Figure 25. Large Molecule Revenue Proportion by Company in 2024
 Figure 26. North America Generic Injectables Revenue 2020-2031 (US$ Million)
 Figure 27. North America Generic Injectables Revenue Market Share by Type (2020-2025)
 Figure 28. North America Generic Injectables Revenue Market Share by Application (2020-2025)
 Figure 29. Asia-Pacific Generic Injectables Revenue 2020-2031 (US$ Million)
 Figure 30. Asia-Pacific Generic Injectables Revenue Market Share by Region (2020-2031)
 Figure 31. Asia-Pacific Generic Injectables Revenue Market Share by Type (2020-2025)
 Figure 32. Asia-Pacific Generic Injectables Revenue Market Share by Application (2020-2025)
 Figure 33. Europe Generic Injectables Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 34. Europe Generic Injectables Revenue Market Share by Country (2020-2031)
 Figure 35. Europe Generic Injectables Revenue Market Share by Type (2020-2025)
 Figure 36. Europe Generic Injectables Revenue Market Share by Application (2020-2025)
 Figure 37. Latin America Generic Injectables Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 38. Latin America Generic Injectables Revenue Market Share by Country (2020-2031)
 Figure 39. Latin America Generic Injectables Revenue Market Share by Type (2020-2025)
 Figure 40. Latin America Generic Injectables Revenue Market Share by Application (2020-2025)
 Figure 41. Middle East and Africa Generic Injectables Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 42. Middle East and Africa Generic Injectables Revenue Market Share by Country (2020-2031)
 Figure 43. Middle East and Africa Generic Injectables Revenue Market Share by Type (2020-2025)
 Figure 44. Middle East and Africa Generic Injectables Revenue Market Share by Application (2020-2025)
 Figure 45. Generic Injectables Supply Chain (Upstream and Downstream Market)
 Figure 46. Global Production Market Share of Generic Injectables Raw Materials by Region in 2024
 Figure 47. Generic Injectables Distribution Channels
 Figure 48. Global Generic Injectables Percentage 2020-2031: Indirect Sales VS Direct Sales
 Figure 49. Global Generic Injectables Percentage 2020-2031: Online Sales VS Offline Sales
 Figure 50. Bottom-up and Top-down Approaches for This Report
 Figure 51. Data Triangulation
 Figure 52. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5900

This license allows only one user to access the PDF.
Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Generic Injectable Drugs Market Research Report 2024
Generic Sterile Injectable Market
Global Hospital Injectable Drugs Market Research Report 2024
Generic Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Generic Oncology Sterile Injectable Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Sustained Release Injectables Market Research Report 2024
Global Injectable Drug Delivery Market Research Report 2024
Global Generic Injectables for Infectious Diseases Market Research Report 2024
Global Sterile Injectable Drugs Market Research Report 2024
Sterile Injectables Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inhalation Nasal Spray Generic Drugs Market Research Report 2024
Global Pharmaceutical Excipients For Injection Market Research Report 2025
Injectable Drug Delivery Systems Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Small Molecule Sterile Injectable Drugs Market Research Report 2024
Global Sterile Injectables Production Line Market Research Report 2025
Global Generic Anti cancer Injectables Market Research Report 2025
Injectable Peptides Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oncology Generic Injectable Drugs Market Research Report 2024
Global Liquid Formulations Drug Delivery Market Research Report 2025
Global Orally Inhaled Generic Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions